Introduction
============

In the western countries the lifetime risk of developing breast cancer is around 12 %. About 5 %--10 % of breast cancer (BC) and ovarian cancer (OC) are hereditary and 30 %--50 % of these are due to mutations with an autosomal dominant inheritance \[[@B1]\]. Deleterious mutations in the *BRCA1* and *BRCA2* genes are the principal known cause of hereditary BC. They are localized on chromosomes 17q21 and 13q12 respectively \[[@B2],[@B3]\]. They are found in 1/400-1/800 people in the general population \[[@B4]-[@B6]\].

For women with a personal or family history of breast and/or ovarian cancer, *BRCA1/2* full-sequencing and analysis for large genomic rearrangements (LGR) are routinely used to quantify the genetic component of cancer risk. The spectrum of mutations found in *BRCA1*/*2* depends on the studied population, ranging from few founder mutations in some, to a wide spectrum of mutations in others \[[@B7]\].

In Lebanon, breast cancer remains the most frequent type of cancer among women since 1960. In 2005, its age adjusted incidence rate was estimated at 76 new cases per 100.000 by the Public Health Ministry of Lebanon and it is still increasing (<http://www.public-health.gov.lb>). In France, during the same period, it was of 101 new cases per 100.000 according to the National Institute of Cancer (<http://www.e-cancer.fr/>). On the other hand, the median age at diagnosis for BC in Lebanon is 52.5 years, approximately 9 years younger than the European/North American median \[[@B8]\].

Given that a woman with breast cancer is more likely to carry a susceptibility gene mutation the younger she is at the time of diagnosis \[[@B5],[@B9],[@B10]\], one possibility is that the allelic frequency of high penetrance genes in the Lebanese population may be higher than that in Caucasian populations.

In order to determine the spectra and frequency of *BRCA1/2* mutations within the Lebanese population, we studied a cohort of 72 Lebanese unrelated patients with breast cancer.

Subjects and Methods
====================

Participants
------------

From 2001 to 2011, 72 unrelated patients were selected to undergo sequence DNA testing for mutations in *BRCA1/2*. They were referred from a wide variety of settings from all over the country, ranging from private physicians' offices to major academic medical centers, because of elevated risk of a *BRCA1/2* mutation: a personal history of invasive breast cancer and at least one of the following criteria: A) breast cancer at any age at onset in ≥ 2 first- and/or second-degree relatives, B) breast cancer \<50 years in a first- or second-degree relative, C) ovarian cancer in ≥ 2 first- and/or second-degree relatives, D) breast and ovarian cancer in ≥ 2 first- and/or second-degree relatives, E) both breast and ovarian cancer in a single first- or second-degree relative, F) male breast cancer.

Two cases in men with a personal history of sporadic breast cancer were also included.

### *BRCA1 and BRCA2 analysis*

After an informed consent was signed, DNA was extracted from 10 ml of peripheral blood using standard methods \[[@B11]\]. All exons and \> 50 bp of each flanking intron were amplified in a final volume of 50 μl containing 100 ng DNA, 0.25 mM dNTPs, 100 ng of each primer and 0.02 unit of Taq polymerase (Invitrogen Life Technologies, Carlsbad, CA, USA). PCR was performed in an ABI9700 thermocycler (Applied Biosystems, Foster City, CA) with initial denaturation at 94 °C for 5 min, followed by 35 cycles of (95 °C for 30s, specific annealing temperature for 30s, 72 °C for 30s), except for *BRCA1* exons 14 and 15 where 5 cycles were added to the initial 35 cycles. Primers sequences are available on request as well as annealing temperatures of each exon.

PCR products were purified using the illustra^TM^ GFX PCR DNA and Gel Band Purification Kit (GE Healthcare, Buckinghamshire, UK), and resuspended in 40 μl of deionized water. Both strands of the resultant products were sequenced using the BigDye® Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA) under standard conditions. The labeled products were subjected to electrophoresis on an ABI3130 Genetic Analyzer sequencing system (Applied Biosystems, Foster City, CA, USA). Electropherograms were analyzed using Sequence Analysis Software version 5.2 (Applied Biosystems, Foster City, CA, USA) and compared to reference sequences (*BRCA1*: ADNg L78833; ADNc NM_007294.3 and *BRCA2*: ADNg Z74739; ADNc NM_000059.3) using ChromasPro version 1.5 (Technelysium, Queensland, Australia). All deleterious mutations were confirmed first on an independent second amplification and second on a second blood specimen.

Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the reference sequences.

The effect of missense mutations was predicted using the BIC database (<http://research.nhgri.nih.gov>) and the UMD-BRCA1/BRCA2 databases and the prediction programs: SIFT (Sorting Intolerant From Tolerant) (<http://sift.jcvi.org/www/SIFT_Blink_submit.html>), PolyPhen (<http://genetics.bwh.harvard.edu/pph/index.html>), and Align-GVGD from the International Agency for research on Cancer (<http://agvgd.iarc.fr>) \[[@B12],[@B13]\]. Prediction of splicing effect was performed with MaxEntScan using a 15 % variation threshold as proposed by Houdayer *et al.*\[[@B14],[@B15]\].

Identified variations were classified into three categories: deleterious, unclassified variant, and neutral.

Results
=======

The mean age at diagnosis of BC for the seventy-two patients was 41 years old. Thirty-seven patients provided us with their histopathological results. Thirty-one patients had a positive estrogen-receptor (ER) and a positive progesterone-receptor (PR) disease, four patients had a positive ER and a negative PR disease and one patient had a negative ER and a positive PR disease. Only one patient had a triple negative disease and was not found to have any deleterious mutation.

Within this cohort, we identified a total of 38 *BRCA1* and 40 *BRCA2* sequence variants, of which 17 (21.8 %) were novel (not reported in the databases BIC and UMD-BRCA1/BRCA2): 11 (14.1 %) in *BRCA1* and 6 (7.7 %) in *BRCA2* (Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). Five disease-associated *BRCA1* mutations and two disease-associated *BRCA2* mutations were found in this cohort (Figure [1](#F1){ref-type="fig"}).

###### 

**Sequence variants identified in the*BRCA1*gene**

      **Nucleotide Change**      **AA change**    **Number of patients**  **Clinical Relevance (BIC)**   **Variation class^§^**   **Polyphen**   **SIFT**        **Align GVGD**
  ------------------------------ --------------- ------------------------ ------------------------------ ------------------------ -------------- --------------- ----------------
       Missense variations                                                                                                                                       
            250 G \> T           C44F\*                     2             Unknown                        5                        +++            Not tolerated   Class 65
            543 C \> G           P142A\*                    1             Not reported                   Not reported             ++             Not tolerated   Class 0
            585 C \> A           L156I                      1             Not reported                   3                        \+             Not tolerated   Class 0
            655A \> G            Y179C†                     2             Unknown                        1                        +++            Not tolerated   Class 45
            1186A \> G           Q356R                      19            Unknown                        1                        +++            Not tolerated   Class 0
           1575 T \> C           F486L†                     2             Unknown                        1                        \+             Tolerated       Class 0
            1767A \> C           N550H†                     2             Unknown                        1                        ++             Not tolerated   Class 0
           2196 G \> A           D693N                      11            No effect                      1                        \+             Not tolerated   Class 0
            2577A \> G           K820E                      1             Unknown                        1                        \+             Tolerated       Class 0
           2731 C \> T           P871L                      47            No effect                      1                        \+             Tolerated       Class 0
            3232A \> G           E1038G                     44            No effect                      1                        \+             Not tolerated   Class 0
           3238 G \> A           S1040N                     2             Unknown                        1                        \+             Tolerated       Class 0
           3646 T \> A           V1176I                     1             Unknown                        Not reported             \+             Tolerated       Class 0
            3667A \> G           K1183R                     43            No effect                      1                        \+             Tolerated       Class 0
           4755 G \> A           D1546N                     1             Unknown                        1                        \+             Tolerated       Class 0
           4773 T \> C           Y1552H                     1             Not reported                   3                        ++             Tolerated       Class 0
            4956A \> G           S1613G                     45            No effect                      1                        \+             Not tolerated   Class 0
           5075 G \> A           M1652I                     2             Unknown                        1                        \+             Tolerated       Class 0
        Nonsense mutations                                                                                                                                       
           5563 G \> A           W1815X                     2             Deleterious                    5                                                        
             Synonyms                                                                                                                                            
           1964 T \> C           S615S                      2             Not reported                   Not reported                                             
           2201 C \> T           S694S                      47            No effect                      1                                                        
           2430 T \> C           L771L                      45            No effect                      1                                                        
           4427 T \> C           S1436S                     44            Unknown                        1                                                        
           5306 G \> C           L1729L                     1             Not reported                   Not reported                                             
   UTRs and Intronic variations                                                                                                                                  
            66-67delTA           5'-UTR                     29            Not reported                   Not reported                                             
          IVS2-91A \> G                                     1             Not reported                   Not reported                                             
         IVS5 + 45 T \> A                                   1             Not reported                   Not reported                                             
         IVS6 + 55 G \> A                                   2             Not reported                   3                                                        
         IVS7 + 15delTTC                                    6             Not reported                   Not reported                                             
          IVS7-34 C \> T                                    17            No effect                      1                                                        
           IVS8-58delT                                      10            No effect                      1                                                        
        IVS11 + 106 G \> A                                  64            Not reported                   Not reported                                             
        IVS13 + 117 G \> A                                  8             Unknown                        Not reported                                             
         IVS14-63 C \> G                                    25            Not reported                   Not reported                                             
        IVS18 + 66 G \> A                                   44            No effect                      1                                                        
         IVS19-26 G \> A                                    2             Not reported                   Not reported                                             
        IVS22 + 68 T \> C                                   1             Unknown                        3                                                        
        c.5711 + 36 C \> G       3'-UTR                     1             Not reported                   Not reported                                             

† Missense considered deleterious when associated.

\*Missense considered deleterious.

Polyphen: +++ Variant predicted to be probably damaging, ++ Variant predicted to be possibly damaging, + Variant predicted to be benign.

UMD-BRCA1/2: 1 Variant considered neutral, 2 Variant considered likely-neutral, 3 Variant considered unclassified, 4 Variant considered likely-causal, 5 Variant considered causal.

^§^ in the UMD-BRCA1 database (<http://www.umd.be/BRCA1/>) (12) using classification system in five classes (13).

###### 

**Sequence variants identified in the*BRCA2*gene**

      **Nucleotide Change**      **AA change**    **Number of patients**  **Clinical Relevance (BIC)**   **Variation class^§^**   **Polyphen**   **SIFT**        **Align GVGD**
  ------------------------------ --------------- ------------------------ ------------------------------ ------------------------ -------------- --------------- ----------------
       Frameshift mutations                                                                                                                                      
         5804_5808delTTAA        I1859KfsX3                 1             Deleterious                    5                                                        
        c.9485-1 G \> A\*                                   1             Not reported                   Not reported                                             
       Missense variations                                                                                                                                       
            353A \> G            Y42C                       1             Unknown                        1                        +++            Tolerated       Class 0
            1093A \> C           N289H                      6             No effect                      1                        \+             Not tolerated   Class 0
            1342A \> C           N372H                      20            No effect                      1                        \+             Tolerated       Class 0
            3199A \> G           N991D                      2             Unknown                        1                        ++             Tolerated       Class 0
           5972 C \> T           T1915M                     2             Unknown                        1                        ++             Tolerated       Class 0
           6359 G \> C           G2044A                     1             Unknown                        3                        \+             Tolerated       Class 0
           6550 C \> T           R2108C                     1             Unknown                        3                        +++            Tolerated       Class 0
           7625 C \> T           A2466V                     26            Unknown                        1                        \+             Not tolerated   Class 0
           9079 G \> A           A2951T                     1             No effect                      2                        \+             Not tolerated   Class 55
        Nonsense mutations                                                                                                                                       
           10204A \> T           K3326X                     1             No effect                      1                                                        
             Synonyms                                                                                                                                            
            1593A \> G           S455S                      6             No effect                      1                                                        
           2457 T \> C           H743H                      6             Unknown                        1                                                        
            3624A \> G           K1132K                     16            No effect                      1                                                        
           4035 T \> C           V1269V                     13            No effect                      1                                                        
            4791A \> G           L1521L                     38            No effect                      2                                                        
           5718 C \> T           S1830S                     1             Not reported                   Not reported                                             
           6741 C \> G           V2171V                     38            Unknown                        1                                                        
            7470A \> G           S2414S                     13            No effect                      1                                                        
           10338 G \> A          R3370R                     1             Unknown                        1                                                        
   UTRs and Intronic variations                                                                                                                                  
            203 G \> A           5'UTR                      16            No effect                      Not reported                                             
         IVS4 + 67A \> C                                    6             Unknown                        1                                                        
        IVS4 + 147 G \> T                                   4             Not reported                   Not reported                                             
         IVS6 + 14 C \> T                                   1             Unknown                        3                                                        
        IVS7 + 183 T \> A                                   21            Not reported                   1                                                        
           IVS7-9A \> G                                     1             Unknown                        Not reported                                             
         IVS8 + 56 C \> T                                   8             Unknown                        1                                                        
         IVS10-34 C \> A                                    1             Not reported                   3                                                        
         IVS10-51 G \> T                                    1             Not reported                   1                                                        
        IVS11 + 80delTTAA                                   10            Unknown                        3                                                        
         IVS12-120 T \> C                                   37            Not reported                   3                                                        
     IVS13 + 133insATTATAAAA                                5             Not reported                   Not reported                                             
        IVS13 + 273 G \> A                                  2             Not reported                   Not reported                                             
        IVS14 + 53 C \> T                                   4             No effect                      Not reported                                             
         IVS16-14 T \> C                                    25            No effect                      1                                                        
         IVS21-66 T \> C                                    25            No effect                      1                                                        
        IVS22 + 53 C \> G                                   1             Not reported                   Not reported                                             
         IVS24-16 T \> C                                    1             Unknown                        1                                                        
        10485 + 105A \> C        3'UTR                      15            Not reported                   Not reported                                             

\*Missense considered deleterious.

Polyphen: +++ Variant predicted to be probably damaging, ++ Variant predicted to be possibly damaging, + Variant predicted to be benign.

UMD-BRCA1/2: 1 Variant considered neutral, 2 Variant considered likely-neutral, 3 Variant considered unclassified, 4 Variant considered likely-causal, 5 Variant considered causal.

^§^ in the UMD-BRCA1 database (<http://www.umd.be/BRCA1/>) (12) using classification system in five classes (13).

![**Pedigrees of the families presenting*BRCA1*(A-E) and*BRCA2*(F,G) mutations.**Squares and circles with solid dark color indicate the affected individuals. The dots in the squares and circles with solid dark color indicate the affected individuals.](1897-4287-10-7-1){#F1}

Six out of the 38 variants found in *BRCA1* (15.8 %) were found to be of uncertain clinical significance according to BIC and UMD. Nineteen variants were known polymorphisms, 14 were intronic variants, 1 was a nonsense mutation (p.W1815X), and 23 missense variations (Table [1](#T1){ref-type="table"}), out of which two were found of interest: p.C44F and p.P142A \[[@B16],[@B17]\]. The first one was associated with a strong family history of breast and ovarian cancer in two unrelated families and the second one was found in a large family with many affected women of different age of onset. One patient presented the association of the three missense variations: p.Y179C, p.F486L and p.N550H, and one patient the variations p.N550H and p.F486L. In 41 patients (57 %) a haplotype presenting the combination of the following variations: p.S694S, p.L771L, p.P871L, p.E1038G, p.K1183R, p.S1436S, p.S1613G and IVS18 + 66 G \> A, was found. In 9 of those, an additional variation, p.Q356R, was found. The *BRCA1* p.Y1552H variation was the only mutation associated to the frequent haplotype found in our population.

Nine out of the 40 variants found in *BRCA2* (22.5 %) were of uncertain clinical significance according to BIC and UMD databases. Twenty-three were known polymorphisms out of which one nonsense variation (p.K3326X). Eighteen variants were missense variations, 19 intronic variants, and 2 frameshift mutations (Table [2](#T2){ref-type="table"}). For the latter, the first one, c.5576_5579delTTAA in exon 11, is a deletion of 4 bases pairs leading to a frameshift and a stop codon three amino acids further down (p.I1859KfsX3). This mutation was identified in a patient diagnosed at the age of 51 years and was considered as a truncating mutation. The family history of this individual included a breast cancer diagnosed in the mother at 63 years. The second mutation is at position c.9485-1 G \> A leading to exon 26 skipping. It was identified in a patient diagnosed at the age of 33 years. The family history of this individual included a breast cancer diagnosis of the father and the paternal aunt.

No variant was predicted to affect splicing except the *BRCA2* c.9485-1 G \> A mutation which disrupts an acceptor splice site consensus sequence.

Discussion
==========

In the present study, we have identified *BRCA1* and *BRCA2* germline deleterious mutations in 9 carriers among a cohort of 72 unrelated Lebanese patients with BC, providing a frequency of mutations which represents a prevalence of 12.5 %.

The low prevalence of mutations found in our population in comparison to other ones \[[@B5],[@B18]-[@B20]\], can be explained either by the genetic testing criteria, or by the possibility that some mutations were missed since we could not look for deletions or duplications of entire exons. Consanguinity might be also an equivocal risk-modifying factor \[[@B21],[@B22]\]. Indeed, the Lebanese population has a relatively high rate of consanguinity (around 15--20 %), and association studies on consanguinity and breast cancer, and the frequency of *BRCA*1 and *BRCA2* in highly consanguineous populations pointed that consanguinity might lead to decreased incidence of breast cancer \[[@B23]\]. Nevertheless, other studies obtained contradictory results and the question remains open \[[@B23]\].

Our findings could not contribute in understanding the cause of the high incidence of BC in Lebanon and the lower age of onset observed compared to western countries. The low age of onset was also reported in other Asian countries, and Arab countries in the Middle East \[[@B24]-[@B26]\]. It may be explained by the differences in exposure to female hormones, diet, physical activity, or other factors. For instance, the "Westernization" of these populations is due to delayed childbearing, lower parity, reduced breast-feeding, decreased exercise and dietary changes \[[@B24]\]. It can lead to a 'cohort effect' where the younger cohort have increased breast cancer risk compared to their mothers and grandmothers, thus giving rise to an apparent lower mean age of onset \[[@B25]\].

In *BRCA1*, a haplotype presenting the combination of the variations: p.S694S, p.L771L, p.P871L, p.E1038G, p.K1183R, p.S1436S, p.S1613G and IVS18 + 66 G \> A was very often found in the Lebanese population. In fact, Dunning *et al*. reported a close to complete allelic association between the alleles at the 871, 1038 and 1613 residues \[[@B27]\]. Freedman *et al.* also reported this haplotype, except for the p.S694S variation, with a frequency of 32 % \[[@B28]\]. The latter study found no significant differences of frequencies between patients and control groups \[[@B28]\].

A major problem, the pathogenic status of several sequence variants that are novel or considered of unknown clinical significance, remains unresolved. For instance, a patient had the association of three missense variations: p.Y179C, p.F486L and p.N550H. Taken separately these variations were considered few years ago non or mildly pathogenic, while this haplotype has recently been considered to alter the protein function of BRCA1 \[[@B29]\]. In another patient, two variations were found: p.F486L and p.N550H. We considered the result as pathogenic. Analyzing the cosegregation of the variations with the cancer phenotype within the family can help resolving this problem, but the high cost and the reluctance of the families to undergo the screening prevent proceeding with this study.

To date, no other mutational analysis on breast cancer has been conducted in Lebanon. This report helps determining the spectrum of *BRCA1/2* point mutations in our country and must be the beginning of other studies with a larger cohort in order to determine the prevalence of the mutations in the general population and to check for the existence of founder mutations given that each of the following mutations p.C44F and p.W1815X were found twice in this cohort. It will be also interesting to evaluate the differences of *BRCA1/2* mutations frequencies among women of diverse ethnicities in Lebanon (Muslims and Christians) or more importantly, whether ethnicity should be taken into account in *BRCA1/2* risk assessment. The answers are important considering the eligibility for genetic testing, and the adoption of targeted prevention strategies.
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